News
UPC
1.930
+7.82%
0.140
Weekly Report: what happened at UPC last week (1111-1115)?
Weekly Report · 6d ago
Universe Pharmaceuticals Inc trading halted, news pending
TipRanks · 11/16 00:55
Universe Pharmaceuticals Announces Share Consolidation Plan
TipRanks · 11/13 13:29
Universe Pharmaceuticals announces share consolidation
TipRanks · 11/13 13:22
Universe Pharmaceuticals to implement share consolidation
Seeking Alpha · 11/13 13:10
BRIEF-Universe Pharmaceuticals Announces Share Consolidation
Reuters · 11/13 13:05
Weekly Report: what happened at UPC last week (1104-1108)?
Weekly Report · 11/11 10:23
Weekly Report: what happened at UPC last week (1028-1101)?
Weekly Report · 11/04 10:23
Universe Pharmaceuticals Faces Nasdaq Compliance Challenge
TipRanks · 11/01 20:32
Universe Pharmaceuticals receives non-compliance letter from Nasdaq
Seeking Alpha · 11/01 20:16
Universe Pharmaceuticals receives Nasdaq notification over bid price deficiency
TipRanks · 11/01 20:05
UNIVERSE PHARMACEUTICALS INC RECEIVES NASDAQ NOTIFICATION REGARDING MINIMUM BID PRICE DEFICIENCY
Reuters · 11/01 20:00
Weekly Report: what happened at UPC last week (1021-1025)?
Weekly Report · 10/28 10:17
Weekly Report: what happened at UPC last week (1014-1018)?
Weekly Report · 10/21 10:16
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 10/18 20:30
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 10/16 16:30
Weekly Report: what happened at UPC last week (1007-1011)?
Weekly Report · 10/14 10:32
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/11 16:31
Universe Pharmaceuticals Confirms Financial Filing Accuracy
TipRanks · 10/10 20:27
Weekly Report: what happened at UPC last week (0930-1004)?
Weekly Report · 10/07 10:25
More
Webull provides a variety of real-time UPC stock news. You can receive the latest news about Universe Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About UPC
Universe Pharmaceuticals Inc is a China-based holding company mainly engaged in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives (TCMD) products targeting the elderly. Through its subsidiary, the Company sells TCMD products, biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements manufactured by third-party pharmaceutical companies. Its TCMD products fall into two categories: chronic condition treatments as well as cold and flu medications, including Guben Yanling Pill, Shenrong Weisheng Pill, Fengshitong Medicinal Liquor, Isatis Root Granule and Qiangli Pipa Syrup. Its major customers are pharmaceutical companies, hospitals, clinics and drugstore chains. The Company mainly conducts its businesses within the Chinese market.